CLDX Celldex Therapeutics Inc

Price (delayed)

$41.97

Market cap

$2.35B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.92

Enterprise value

$2.31B

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which ...

Highlights
The company's gross profit has surged by 192% YoY and by 58% QoQ
Celldex Therapeutics's revenue has soared by 192% YoY and by 58% from the previous quarter
CLDX's quick ratio has surged by 62% since the previous quarter but it is down by 17% year-on-year
Celldex Therapeutics's net income has decreased by 26% YoY and by 13% from the previous quarter
CLDX's EPS is down by 22% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of CLDX
Market
Shares outstanding
55.9M
Market cap
$2.35B
Enterprise value
$2.31B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.62
Price to sales (P/S)
295.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
336.17
Earnings
Revenue
$6.88M
EBIT
-$141.43M
EBITDA
-$138.42M
Free cash flow
-$109.11M
Per share
EPS
-$2.92
Free cash flow per share
-$2.25
Book value per share
$9.08
Revenue per share
$0.14
TBVPS
$9.05
Balance sheet
Total assets
$465.63M
Total liabilities
$36.46M
Debt
$2.54M
Equity
$429.17M
Working capital
$400.57M
Liquidity
Debt to equity
0.01
Current ratio
13.87
Quick ratio
13.69
Net debt/EBITDA
0.23
Margins
EBITDA margin
-2,011.1%
Gross margin
100%
Net margin
-2,054.8%
Operating margin
-2,245.3%
Efficiency
Return on assets
-41.3%
Return on equity
-45%
Return on invested capital
-54.1%
Return on capital employed
-32.5%
Return on sales
-2,054.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
0.43%
1 week
2.34%
1 month
-18.3%
1 year
20.67%
YTD
5.82%
QTD
5.82%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$6.88M
Gross profit
$6.88M
Operating income
-$154.54M
Net income
-$141.43M
Gross margin
100%
Net margin
-2,054.8%
The company's gross profit has surged by 192% YoY and by 58% QoQ
Celldex Therapeutics's revenue has soared by 192% YoY and by 58% from the previous quarter
CLDX's operating margin has surged by 57% year-on-year and by 27% since the previous quarter
The net margin has soared by 57% YoY and by 28% QoQ

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
4.62
P/S
295.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
336.17
CLDX's EPS is down by 22% YoY and by 10% from the previous quarter
Celldex Therapeutics's equity has soared by 74% from the previous quarter and by 32% YoY
The P/B is 32% higher than the 5-year quarterly average of 3.5 but 13% lower than the last 4 quarters average of 5.3
Celldex Therapeutics's revenue has soared by 192% YoY and by 58% from the previous quarter
CLDX's price to sales (P/S) is 27% lower than its last 4 quarters average of 402.2 and 14% lower than its 5-year quarterly average of 345.0

Efficiency

How efficient is Celldex Therapeutics business performance
CLDX's ROS has soared by 57% YoY and by 28% from the previous quarter
Celldex Therapeutics's ROIC has plunged by 53% YoY and by 3.2% from the previous quarter
The ROE has contracted by 44% YoY and by 4.2% from the previous quarter
The ROA is down by 42% YoY and by 4% QoQ

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
Celldex Therapeutics's total assets has soared by 66% from the previous quarter and by 32% YoY
CLDX's quick ratio has surged by 62% since the previous quarter but it is down by 17% year-on-year
The debt is 99% lower than the equity
Celldex Therapeutics's equity has soared by 74% from the previous quarter and by 32% YoY
The debt has decreased by 37% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.